Reltecimod

Modify Date: 2024-01-02 19:55:08

Reltecimod structure	Common Name	Reltecimod
	CAS Number	1447799-33-8	Molecular Weight	1037.187
	Density	1.3±0.1 g/cm3	Boiling Point	1473.8±65.0 °C at 760 mmHg
	Molecular Formula	C₄₆H₇₂N₁₀O₁₅S	Melting Point	N/A
	MSDS	N/A	Flash Point	845.1±34.3 °C

Use of Reltecimod

Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs)[1][2].

Name	Reltecimod
Synonym	More Synonyms

Description	Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs)[1][2].
Related Catalog	Research Areas >> Infection Research Areas >> Inflammation/Immunology Signaling Pathways >> Anti-infection >> Bacterial
Target	TP44, Bacteria[1][2]
In Vivo	Reltecimod (1.25-5 mg/kg; i.v.) increases the survival rate of mice infected with different bacteria[2]. Animal Model: Pathogen-free, female BALB/c mice (Acute bacterial peritonitis was induced by i.p. administration with E. coli 018:K1)[2] Dosage: 1.25 or 5 mg/kg Administration: i.v.; single dosage; at 4 h post infection Result: Resulted in 100% survival at single dosage of 5 mg/kg, at day 6. Resulted in 70% survival at 4 dosage (at 1, 12, 24 and 36 h post infection) of 1.25 mg/kg, at day 6. Animal Model: Pathogen-free, female BALB/c mice (NSTI induced by thigh i.m. administration with Streptococcus pyogenes)[2] Dosage: 2.5 or 5 mg/kg Administration: i.v.; single dosage; at 1 h, or at 1 h and 12 or 72 h post infection Result: Resulted in 65% survival at single dosage of 2.5 mg/kg, at day 8. Resulted in 30% survival at two dosage (1 and 12 h post infection) of 2.5 mg/kg, at day 8. Resulted in 90% survival at single dosage (1 h post infection) of 5 mg/kg, at day 6. Animal Model: Pathogen-free, female BALB/c mice [Cecal ligation and puncture (CLP) model][2] Dosage: 1.25, 2.5, or 5 mg/kg Administration: i.v.; single dosage Result: Increased day 7 survival by up to 100%.
References	[1]. Shirvan, A., et al. Reltecimod. T-cell-specific surface glycoprotein CD28 (TP44) antagonist, CD28 homodimer interface mimetic peptide, Treatment of necrotizing soft-tissue infection. Drugs Fut 2018, 43(4): 243 [2]. Edgar, R., Tarrio, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. Int J Pept Res Ther 26, 1669–1683 (2020).

Density	1.3±0.1 g/cm3
Boiling Point	1473.8±65.0 °C at 760 mmHg
Molecular Formula	C₄₆H₇₂N₁₀O₁₅S
Molecular Weight	1037.187
Flash Point	845.1±34.3 °C
Exact Mass	1036.489990
LogP	1.38
Vapour Pressure	0.0±0.3 mmHg at 25°C
Index of Refraction	1.573